Boland BS - Search Results

1

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. Narula N, et al. Among authors: boland bs. Am J Gastroenterol. 2018 Dec;113(12):696. doi: 10.1038/s41395-018-0401-4. Am J Gastroenterol. 2018. PMID: 30390030 Free PMC article.

2

Update on Janus kinase antagonists in inflammatory bowel disease.

Boland BS, Sandborn WJ, Chang JT. Boland BS, et al. Gastroenterol Clin North Am. 2014 Sep;43(3):603-17. doi: 10.1016/j.gtc.2014.05.011. Epub 2014 Jun 24. Gastroenterol Clin North Am. 2014. PMID: 25110261 Free PMC article. Review.

3

Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease.

Boland BS, Dulai PS, Chang M, Sandborn WJ, Levesque BG. Boland BS, et al. Am J Gastroenterol. 2015 Nov;110(11):1631-2. doi: 10.1038/ajg.2015.326. Am J Gastroenterol. 2015. PMID: 26618431 Free PMC article. No abstract available.

4

How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.

Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. Dulai PS, et al. Among authors: boland bs. Inflamm Bowel Dis. 2016 Apr;22(4):998-1009. doi: 10.1097/MIB.0000000000000661. Inflamm Bowel Dis. 2016. PMID: 26835982 Free PMC article. Review.

5

Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis.

Boland BS, Bagi P, Valasek MA, Chang JT, Bustamante R, Madlensky L, Sandborn WJ, Harismendy O, Gupta S. Boland BS, et al. Am J Gastroenterol. 2016 May;111(5):746-8. doi: 10.1038/ajg.2016.92. Am J Gastroenterol. 2016. PMID: 27151126 Free PMC article. No abstract available.

6

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.

Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. Dulai PS, et al. Among authors: boland bs. Am J Gastroenterol. 2016 Aug;111(8):1147-55. doi: 10.1038/ajg.2016.236. Epub 2016 Jun 14. Am J Gastroenterol. 2016. PMID: 27296941

7

Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation.

Boland BS, Riedl MA, Valasek MA, Crowe SE, Sandborn WJ. Boland BS, et al. Am J Gastroenterol. 2017 Oct;112(10):1621. doi: 10.1038/ajg.2017.246. Am J Gastroenterol. 2017. PMID: 28978958 Free PMC article. No abstract available.

8

Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease.

Moustafa A, Li W, Anderson EL, Wong EHM, Dulai PS, Sandborn WJ, Biggs W, Yooseph S, Jones MB, Venter JC, Nelson KE, Chang JT, Telenti A, Boland BS. Moustafa A, et al. Among authors: boland bs. Clin Transl Gastroenterol. 2018 Jan 18;9(1):e132. doi: 10.1038/ctg.2017.58. Clin Transl Gastroenterol. 2018. PMID: 29345635 Free PMC article.

9

Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.

Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Singh S, et al. Among authors: boland bs. J Crohns Colitis. 2018 May 25;12(6):635-643. doi: 10.1093/ecco-jcc/jjy004. J Crohns Colitis. 2018. PMID: 29370397 Free PMC article. Review.

10

Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series.

Park S, Evans E, Sandborn WJ, Boland B. Park S, et al. Am J Gastroenterol. 2018 Apr;113(4):627-629. doi: 10.1038/ajg.2018.22. Am J Gastroenterol. 2018. PMID: 29610516 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

112 results

Search Page

Filters